Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer's Disease

Yixuan Yang,Lina Qiu

DOI: https://doi.org/10.3390/brainsci14060590

IF: 3.333

2024-06-10

Brain Sciences

Abstract:As the population ages worldwide, Alzheimer's disease (AD), the most prevalent kind of neurodegenerative disorder among older people, has become a significant factor affecting quality of life, public health, and economies. However, the exact pathogenesis of Alzheimer's remains elusive, and existing highly recognized pathogenesis includes the amyloid cascade hypothesis, Tau neurofibrillary tangles hypothesis, and neuroinflammation hypothesis. The major diagnoses of Alzheimer's disease include neuroimaging positron emission computed tomography, magnetic resonance imaging, and cerebrospinal fluid molecular diagnosis. The therapy of Alzheimer's disease primarily relies on drugs, and the approved drugs on the market include acetylcholinesterase drugs, glutamate receptor antagonists, and amyloid-β monoclonal antibodies. Still, the existing drugs can only alleviate the symptoms of the disease and cannot completely reverse it. This review aims to summarize existing research results on Alzheimer's disease pathogenesis, diagnosis, and drug therapy, with the objective of facilitating future research in this area.

neurosciences

What problem does this paper attempt to address?

This paper reviews the research progress on the pathogenesis, diagnosis, and drug treatment of Alzheimer's disease (AD). AD is the most common neurodegenerative disease, and its impact on quality of life, public health, and economy is increasingly significant with the global aging population. Although the exact pathogenesis is not yet clear, the current main hypotheses include the amyloid cascade hypothesis, the tau neurofibrillary tangle hypothesis, and the neuroinflammation hypothesis.

In terms of diagnosis, non-invasive positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid molecular diagnosis are used in clinical practice. Although these methods have their advantages and disadvantages, such as PET being expensive and unable to accurately distinguish AD from other neurodegenerative diseases, and cerebrospinal fluid diagnosis being accurate but invasive.

Currently, the treatment of AD mainly relies on drugs, including acetylcholinesterase inhibitors, glutamate receptor antagonists, and β-amyloid monoclonal antibodies. However, the existing drugs can only alleviate symptoms and cannot completely reverse the disease. Recently, some new drugs such as Aducanumab, Lecanemab, and Sodium Oligomannate targeting the gut-brain axis have been approved for marketing.

The paper aims to summarize the existing achievements in AD research and provide guidance for future research. The authors discuss the interactions between various hypotheses, diagnostic methods, and technologies, and list FDA-approved drugs along with their efficacy and side effects, in order to draw lessons from past research and promote further research on AD.